Daniel leads the late-stage oncology pipeline & portfolio planning group at Genentech. His team supports maximizing the value of the oncology portfolio by facilitating the creation, assessment, & valuation of clinical trial alternatives. He joined Genentech 3 years ago, initially supporting the Skin Franchise & Lung Disease Area Team followed by Cancer Immunotherapy. Prior to joining Genentech, Daniel worked at Bristol-Myers Squibb, originally as a biomarker/protocol statistician, before transitioning to their portfolio planning group. He holds a BA in physics from Rice University, MA in statistics & PhD in social psychology from the University of Michigan.